Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 6, 2010, Pages 741-754

  Del Vecchio, CaTherine A ^a   Wong, Albert J ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CDX 110; PEPTIDE VACCINE; RINDOPEPIMUT; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; LYMPHOCYTOPENIA; NEUROLOGIC DISEASE; NONHUMAN; PAIN; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SKIN DISEASE;

ANIMALS; BRAIN NEOPLASMS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; GLIOBLASTOMA; HUMANS; INJECTIONS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VACCINES, SUBUNIT;

ANIMALIA;

EID: 79952907554     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (122)

1. Effects of treatment on long-term survivors with malignant astrocytomas. Imperato JP, Paleologos NA, Vick NA ANN Neurol 1990 28 6 818-822
2. Untangling the ErbB signalling network. Yarden Y, Sliwkowski MX Nat Rev Mol Cell Biol 2001 2 2 127-137 (Pubitemid 33674041) (Pubitemid 33674041)
3. AstraZeneca's annual business review 2002 analyst pResentation. AstraZeneca plc Company Presentation 2002 November 07
4. Growth suppRession of intracranial xenografted glioblastomas overexpRessing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Mishima K, Johns TG, Luwor RB, Scott AM, Stockert E, Jungbluth AA, Ji XD, Suvarna P, Voland JR, Old LJ, Huang HJS et al Cancer Res 2001 61 14 5349-5354 (Pubitemid 32694908) (Pubitemid 32694908)
5. RNA in Drug development-The knowledge foundation's third annual conference, RNA as a tool and target, San Diego, CA, USA. IDDB author IDDB MEETING REpORT 2003 November 10
6. Structural alterations of the epidermal growth factor receptor Gene in human gliomas. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, Vogelstein B Proc Natl Acad Sci USA 1992 89 7 2965-2969
7. Q4/2003: Merck KGaA's annual operating Result rises 19% to Eur 736 million. Merck KGaA Press Release 2004 February 16
8. Alteris licenses rights from Duke and Johns Hopkins to Cancer vaccine targeting variant EGF receptor. Alteris Therapeutics Inc Press Release 2004 February 18
9. OSI Pharmaceuticals announces launch of Tarceva. OSI Pharmaceuticals Inc Press Release 2004 November 22
10. Celldex announces acquisition of Lorantis Limited and assets of Alteris Therapeutics Inc. Celldex Therapeutics Inc Press Release 2005 October 12
11. Cancer immunoTherapeutics and vaccines-CHI's third annual conference, Cambridge, MA, USA. Salgaller M IDDB MEETING REpORT 2006 August 22-23
12. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M et al Clin Cancer Res 2006 12 16 4899-4907 (Pubitemid 44338577) (Pubitemid 44338577)
13. Amgen's third quarter 2006 adjusted earnings per share, excluding stock option expense, increased 22 percent to $1.04. Amgen Inc Press Release 2006 October 23
14. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fuoropyrimidines. Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, Mirtsching B, Cohn AL, Pippas AW, Azarnia N, Tsuchihashi Z et al J Clin Oncol 2006 24 30 4914-4921 (Pubitemid 46630920) (Pubitemid 46630920)
15. Merck annual report 2006-More potential. Merck KGaA Annual Report 2007 March 01
16. NCT00458601: Phase II/III study of CDX-110 in patients with GBM (ACT III). Celldex Therapeutics Inc CLINICALTRIALS.GOV 2007
17. Cetuximab for the treatment of colorectal Cancer. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu DS, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC et al N Engl J Med 2007 357 20 2040-2048 (Pubitemid 350106711) (Pubitemid 350106711)
18. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M et al J Clin Oncol 2007 25 30 4722-4729 (Pubitemid 350086473) (Pubitemid 350086473)
19. FDA grants Celldex's CDX-110 Orphan Drug status for glioblastoma. Celldex Therapeutics Inc Press Release 2007 December 07
20. RadioTherapy plus concomitant and adjuvant temozolomide for glioblastoma. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J et al N Engl J Med 2005 352 10 987-996 (Pubitemid 40349501) (Pubitemid 40349501)
21. Record operating Results for Roche again in 2007. Roche Holding AG Press Release 2008 January 30
22. EGFRvIII vaccine (CDX-110) alone and with simultaneous temozolomide in patients with newly diagnosed, Resected, EGFRVIII positive GBM. Heimberger A, Davis T, Keler T, Vitale L, Sampson J J Immunother 2007 30 8 883
23. AVANT announces completed merger with Celldex and 1-for-12 reverse stock split. AVANT ImmunoTherapeutics Inc Press Release 2008 March 07
24. Pfzer and AVANT enter into licensing and development agreement for novel Therapeutic vaccine candidate for brain Cancer. Pfzer Inc Press Release 2008 April 16
25. EGFRvIII vaccine-specifc induction of humoral and cell-mediated Immunity. Ramakrishna V, Beacock-Sharp H, Ward G, He LZ, Dillon J, Young L, MerryweaTher A, Champion B, Keler T J Immunother 2006 29 6 649
26. Induction of an anti-EGFRvIII immunological Response with dendritic cells loaded with an EGFRvIII-specifc peptide is curative for intracranial tumor. Heimberger AB, Archer GE, Crotty LE, Friedman AH, Friedman HS, Bigner DD, Sampson JH Proc Am Assoc Cancer Res 2000 41 Abs 1381
27. Immunological Responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunoTherapy: Case study. Heimberger AB, Sun W, Hussain SF, Dey M, Crutcher L, Aldape K, Gilbert M, Hassenbusch SJ, Sawaya R, Schmittling B, Archer GE et al Neurooncology 2008 10 1 89-103
28. Peptide vaccination induces a Therapeutic humoral Response to mutant epidermal growth factor receptor expRessing tumors. Archer GE, Crotty L, Friedman AH, Friedman HS, Bigner DD, Sampson JH pROC AM ASSOC Cancer Res 2000 41 Abs 5067
29. Induction of immunologic and clinical Responses with EGFRvIII-targeted vaccine (CDX-110) with cycles of temozolomide in patients with newly diagnosed EGFRvIII-positive GBM. Archer GE, Heimberger AB, Bigner DD, Davis T, Friedman HS, Keler T, McLendon RE, Mitchell DA, Reardon D, Sawaya R, Vredenberg J et al Neurooncology 2009 11 2 Abs 13
30. Epidermal growth factor receptor variant III (EGFRvIII) vaccine (CDX-110) in GBM. Heimberger AB, Archer GE, Mitchell DA, Bigner DD, Schmittling RJ, Herndon JE, Davis T, Friedman HS, Keler T, Reardon DA, Sampson JH J Clin Oncol 2009 27 Suppl 15 Abs 2021
31. Effect of daclizumab on TReg counts and EGFRvIII-specifc immune Responses in GBM. Sampson JH, Archer GE, Bigner DD, Schmittling RJ, Herndon JE, Davis T, Friedman HS, Keler T, Reardon DA, Mitchell DA J Clin Oncol 2009 27 15 Suppl Abs 2034
32. Epidermal growth factor receptor vIII peptide vaccination is effcacious against established intracerebral tumors. Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH Clin Cancer Res 2003 9 11 4247-4254 (Pubitemid 37204046) (Pubitemid 37204046)
33. Comprehensive genomic characterization defnes human glioblastoma Genes and core pathways. Chin L, Meyerson M, Aldape K, Bigner D, Mikkelsen T, VandenBerg S, Kahn A, Penny R, Ferguson ML, Gerhard DS, Getz G et al Nature 2008 455 7216 1061-1068
34. Phase II trial of vorinostat in recurrent glioblastoma multiforme: A north central Cancer treatment group study. Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A, Nebozhyn M, Fantin VR, Richon VM et al J Clin Oncol 2009 27 12 2052-2058
35. QIAGEN Unit and Pfzer enter into an agreement to develop a companion diagnostic for brain tumor patients. Qiagen NV Press Release 2010 February 04
36. Dendreon conference call. Dendreon Corp Company Presentation 2010 April 29
37. Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progRessive glioblastoma (GB). Wen PY, Prados M, Schiff D, Reardon DA, Cloughesy T, Mikkelsen T, Batchelor T, Drappatz J, Chamberlain MC, De Groot JF J Clin Oncol 2010 28 15 Suppl Abs 2006
38. Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide (TMZ) in patients (pts) with glioblastoma (GBM). Lai R, Recht LD, Reardon DA, Paleologos N, Groves MD, Rosenfeld MR, Meech S, Davis TA, Pavlov D, Sampson JH J Clin Oncol 2010 28 15 Suppl Abs 2014
39. Temozolomide enhances effcacy of EGFRvIII vaccine (CDX-110) in patients with newly-diagnosed GBM. Sampson JH J Neurosurg 2008 108 4 A885
40. The positive infuence of temozolomide on the humoral and cell-mediated (DTH) Responses to EGFRvIII-targeted vaccine (CDX-110) in patients with GBM. Archer G, Heimberger A, Bigner D, Davis T, Friedman H, Friedman A, Keler T, Mitchell D, Reardon D, Sawaya R, Vredenburgh J et al Neurooncology 2008 10 5 Abs IM-12
41. Celldex Therapeutics regains worldwide rights to rindopepimut (CDX-110). Celldex Therapeutics Inc Press Release 2010 September 03
42. Screening for epidermal growth factor receptor mutations in lung Cancer. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A et al N Engl J Med 2009 361 10 958-967
43. Humoral and cell mediated Responses to the EGFRvIII-targeted vaccine (CDX-110) are enhanced with continuous temozolomide in patients with GBM. Archer GE, Heimberger AB, Bigner DD, Davis T, Friedman AH, Friedman HS, Keler T, Mitchell DA, Reardon D, Sawaya R, Vredenberg J et al pROC AM ASSOC Cancer Res 2008 49 Abs LB-310
44. Effect of EGFRvIII-targeted vaccine (CDX-110) on immune Response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. Sampson JH, Archer GE, Bigner DD, Davis T, Friedman HS, Keler T, Mitchell DA, Reardon DA, Sawaya R, Heimberger AB J Clin Oncol 2008 26 15 Suppl Abs 2011
45. Temozolomide as a vaccine adjuvant in GBM. Sampson JH, Aldape KD, Gilbert MR, Hassenbusch SJ, Sawaya R, Schmittling B, Archer GE, Mitchell D, Bigner DD, Reardon DA, Heimberger AB J Clin Oncol 2007 25 18 Suppl Abs 2020
46. Detection of humoral Response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. Schmittling RJ, Archer GE, Mitchell DA, Heimberger A, Pegram C, Herndon JE, Friedman HS, Bigner DD, Sampson JH J Immunol Methods 2008 339 1 74-81
47. Business and fnancial update for the frst quarter of 2010. TiGenix NV Press Release 2010 May 19
48. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Porter KR, McCarthy BJ, Freels S, Kim Y, Davis FG Neurooncology 2010 12 6 520-527
49. Possible future issues in the treatment of glioblastomas: Special emphasis on cell migration and the Resistance of migrating glioblastoma cells to apoptosis. Lefranc F, Brotchi J, Kiss R J Clin Oncol 2005 23 10 2411-2422 (Pubitemid 46218735) (Pubitemid 46218735)
50. Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L et al Genes Dev 2007 21 21 2683-2710 (Pubitemid 350070717) (Pubitemid 350070717)
51. Current management of glioblastoma multiforme. Grossman SA, Batara JF Semin Oncol 2004 31 5 635-644 (Pubitemid 39389014) (Pubitemid 39389014)
52. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan L, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE, Dowell JM et al J Clin Oncol 2005 23 36 9359-9368
53. An integrated genomic analysis of human glioblastoma multiforme. Parsons DW, Jones S, Zhang XS, Lin JCH, Leary RJ, AnGenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A et al Science 2008 321 5897 1807-1812
54. OncoGenes in head and neck Cancer. Irish JC, Bernstein A Laryngoscope 1993 103 1 Pt 1 42-52 (Pubitemid 23028804) (Pubitemid 23028804)
55. Enhanced expRession of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic Cancer. Korc M, Meltzer P, Trent J Proc Natl Acad Sci USA 1986 83 14 5141-5144 (Pubitemid 16051332) (Pubitemid 16051332)
56. Epidermal growth factor receptors in colorectal carcinoma. Moorghen M, Ince P, Finney KJ, Watson AJ, Harris AL Anticancer Res 1990 10 3 605-612
57. Amplifcation and overexpRession of the epidermal growth factor receptor Gene in human renal-cell carcinoma. Ishikawa J, Maeda S, Umezu K, Sugiyama T, Kamidono S Int J Cancer 1990 45 6 1018-1021 (Pubitemid 20201568) (Pubitemid 20201568)
58. ExpRession of growth factors and oncoGenes in normal and tumor-derived human mammary epithelial cells. Zajchowski D, Band V, Pauzie N, Tager A, Stampfer M, Sager R Cancer Res 1988 48 24 7041-7047 (Pubitemid 19013979) (Pubitemid 19013979)
59. Effects of EGF, bFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain-tumour biopsies in vitro. Engebraaten O, Bjerkvig R, Pedersen PH, Laerum OD Int J Cancer 1993 53 2 209-214 (Pubitemid 23042867) (Pubitemid 23042867)
60. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: A model of glioblastoma multiforme pathophysiology. Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY Mol Biol Cell 1993 4 1 121-133 (Pubitemid 23071308) (Pubitemid 23071308)
61. Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth. Shibata T, Kawano T, Nagayasu H, Okumura K, Arisue M, Hamada J, Takeichi N, Hosokawa M Tumor Biol 1996 17 3 168-175 (Pubitemid 26151481) (Pubitemid 26151481)
62. Effcacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal Cancer. Fakih M, Wong R Curr Oncol 2010 17 Suppl 1 S3-17
63. Panitumumab monoTherapy in patients with previously treated metastatic colorectal Cancer. Hecht JR, Patnaik A, Berlin J, Venook A, Malik L, Tchekmedyian S, Navale L, Amado RG, Meropol NJ Cancer 2007 110 5 980-988 (Pubitemid 47312862) (Pubitemid 47312862)
64. Cetuximab shows activity in colorectal Cancer patients with tumors that do not exPress the epidermal growth factor receptor by immunohistochemistry. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS et al J Clin Oncol 2005 23 9 1803-1810 (Pubitemid 46211358) (Pubitemid 46211358)
65. Adverse events associated with anti-EGFR Therapies for the treatment of metastatic colorectal Cancer. Fakih M, Vincent M CURR ONCOL 2010 17 Suppl 1 S18-S30
66. Activating and Resistance mutations of EGFR in non-small-cell lung Cancer: Role in clinical Response to EGFR tyrosine kinase inhibitors. Gazdar AF Oncogene 2009 28 Suppl 1 S24-S31
67. Lessons learnt from geftinib and erlotinib: Key insights into small-Molecule EGFR-targeted kinase inhibitors in non-small cell lung Cancer. Laack E, Sauter G, Bokemeyer C Lung Cancer 2010 69 3 259-264
68. Amplifcation and expRession of the epidermal growth factor receptor Gene in human glioma xenografts. Humphrey PA, Wong AJ, Vogelstein B, Friedman HS, Werner MH, Bigner DD, Bigner SH Cancer Res 1988 48 8 2231-2238
69. Amplifcation of the structurally and functionally altered epidermal growth factor receptor Gene (c-erbB) in human brain tumors. Yamazaki H, Fukui Y, Ueyama Y, Tamaoki N, Kawamoto T, Taniguchi S, Shibuya M Mol Cell Biol 1988 8 4 1816-1820
70. OverexpRession of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Watanabe K, Sato K, Yonekawa Y, Kleihues P, Ohgaki H BRAIN pATHOL 1996 6 3 217-223
71. Frequent expRession of a mutant epidermal growth factor receptor in multiple human tumors. Moscatello DK, HolgadomaDruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL, Wong AJ Cancer Res 1995 55 23 5536-5539
72. ExpRession of mutated epidermal growth factor receptor by non-small cell Lung carcinomas. Garcia De Palazzo IE, Adams GP, SundaReshan P, Wong AJ, Testa JR, Bigner DD, Weiner LM Cancer Res 1993 53 14 3217-3220 (Pubitemid 23223283) (Pubitemid 23223283)
73. Evidence for the differential expRession of a variant EGF receptor protein in human prostate Cancer. Olapade-Olaopa EO, Moscatello DK, MacKay EH, Horsburgh T, Sandhu DPS, Terry TR, Wong AJ, Habib FK Br J Cancer 2000 82 1 186-194 (Pubitemid 30008980) (Pubitemid 30008980)
74. Monoclonal antibodies against EGFRvIII are tumor specifc and react with breast and Lung carcinomas and malignant gliomas. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ, Traweek ST et al Cancer Res 1995 55 14 3140-3148
75. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast Cancer. Tang CK, Gong XQ, Moscatello DK, Wong AJ, Lippman ME Cancer Res 2000 60 11 3081-3087 (Pubitemid 30395838) (Pubitemid 30395838)
76. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplifed rearranged Genes in human glioblastomas. Sugawa N, Ekstrand AJ, James CD, Collins VP Proc Natl Acad Sci USA 1990 87 21 8602-8606
77. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Moscatello DK, Montgomery RB, SundaReshan P, McDanel H, Wong MY, Wong AJ Oncogene 1996 13 1 85-96 (Pubitemid 26248548) (Pubitemid 26248548)
78. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human Cancers is mediated by thReshold levels of constitutive tyrosine phosphorylation and unattenuated signalling. Huang HJS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD, Huang CM, Gill GN, Wiley HS, Cavenee WK J Biol Chem 1997 272 5 2927-2935 (Pubitemid 27053343) (Pubitemid 27053343)
79. Enhanced tumorigenic behavior of glioblastoma cells expRessing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. Prigent SA, Nagane M, Lin H, Huvar I, Boss GR, Feramisco JR, Cavenee WK, Huang HJS J Biol Chem 1996 271 41 25639-25645 (Pubitemid 26337944) (Pubitemid 26337944)
80. A mutant epidermal growth-factor receptor common in human glioma confers enhanced tumorigenicity. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, Huang HJS Proc Natl Acad Sci USA 1994 91 16 7727-7731 (Pubitemid 24238258) (Pubitemid 24238258)
81. ExpRession of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Feldkamp MM, Lala P, Lau N, Roncari L, Guha A Neurosurgery 1999 45 6 1442-1453
82. Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Chu CT, Everiss KD, Wikstrand CJ, Batra SK, Kung HJ, Bigner DD Biochem J 1997 324 Pt 3 855-861 (Pubitemid 27285544) (Pubitemid 27285544)
83. Differential modulation of mitogen-activated protein (MAP) kinase/extracellular signal-related kinase kinase and MAP kinase activities by a mutant epidermal growth factor receptor. Montgomery RB, Moscatello DK, Wong AJ, Cooper JA, Stahl WL J Biol Chem 1995 270 51 30562-30566 (Pubitemid 26005116) (Pubitemid 26005116)
84. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. Moscatello DK, Holgado-MaDruga M, Emlet DR, Montgomery RB, Wong AJ J Biol Chem 1998 273 1 200-206 (Pubitemid 28042194) (Pubitemid 28042194)
85. EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes. Grandal MV, Zandi R, Pedersen MW, Willumsen BM, van DEurs B, Poulsen HS Carcinogenesis 2007 28 7 1408-1417 (Pubitemid 47241789) (Pubitemid 47241789)
86. Hypophosphorylation of Residue Y1045 leads to defective downregulation of EGFRvIII. Han W, Zhang T, Yu H, Foulke JG, Tang CK Cancer Biol Ther 2006 5 10 1361-1368 (Pubitemid 44772265) (Pubitemid 44772265)
87. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD Cancer Res 1997 57 18 4130-4140 (Pubitemid 27427708) (Pubitemid 27427708)
88. The intracellular tyrosine kinase domain of the epidermal growth-factor receptor undergoes a conformational change upon autophosphorylation. Cadena DL, Chan CL, Gill GN J Biol Chem 1994 269 1 260-265 (Pubitemid 24026653) (Pubitemid 24026653)
89. Mutant epidermal growth factor receptor up-regulates Molecular effectors of tumor invasion. Lal A, Glazer CA, Martinson HM, Friedman HS, Archer GE, Sampson JH, Riggins GJ Cancer Res 2002 62 12 3335-3339 (Pubitemid 34651373) (Pubitemid 34651373)
90. Distribution of epidermal growth factor receptor Gene amplifcation in brain tumours and correlation to prognosis. Diedrich U, Lucius J, Baron E, Behnke J, Pabst B, Zoll B J Neurol 1995 242 10 683-688
91. Amplifcation of the epidermal-growth-factor-receptor Gene correlates with different growth behaviour in human glioblastoma. Schlegel J, Merdes A, Stumm G, Albert FK, Forsting M, Hynes N, Kiessling M Int J Cancer 1994 56 1 72-77 (Pubitemid 24044796) (Pubitemid 24044796)
92. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Humphrey PA, Wong AJ, Vogelstein B, Zalutsky MR, Fuller GN, Archer GE, Friedman HS, Kwatra MM, Bigner SH, Bigner DD Proc Natl Acad Sci USA 1990 87 11 4207-4211
93. Immune Responses of breast Cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Δ EGF-R, and de2-7 EGF-R). Purev E, Cai DW, Miller E, Swoboda R, Klein-Szanto A, Marincola FM, Mick R, Otvos L, Wunner W, Birebent B, Somasundaram R et al J IMMUNOL 2004 173 10 6472-6480 (Pubitemid 39487809) (Pubitemid 39487809)
94. Unarmed, tumor-specifc monoclonal antibody effectively treats brain tumors. Sampson JH, Crotty LE, Lee S, Archer GE, Ashley DM, Wikstrandt CJ, Hale LP, Small C, Dranoff G, Friedman AH, Friedman HS et al Proc Natl Acad Sci USA 2000 97 13 7503-7508 (Pubitemid 30431493) (Pubitemid 30431493)
95. Novel monoclonal antibody specifc for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expRessed in cells containing amplifcation of the EGFR Gene. Johns TG, Stockert E, Ritter G, Jungbluth AA, Huang HJS, Cavenee WK, Smyth FE, Hall CM, Watson N, Nice EC, Gullick WJ et al Int J Cancer 2002 98 3 398-408 (Pubitemid 34188683) (Pubitemid 34188683)
96. Monoclonal antibody 806 inhibits the growth of tumor xenografts expRessing eiTher the de2-7 or amplifed epidermal growth factor receptor (EGFR) but not wild-type EGFR. Luwor RB, Johns TG, Murone C, Huang HJS, Cavenee WK, Ritter G, Old LJ, Burgess AW, Scott AM Cancer Res 2001 61 14 5355-5361 (Pubitemid 32694909) (Pubitemid 32694909)
97. A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunoTherapy of tumors. Moscatello DK, Ramirez G, Wong AJ Cancer Res 1997 57 8 1419-1424 (Pubitemid 27175553) (Pubitemid 27175553)
98. Keyhole limpet hemocyanin (KLH): A biomedical review. Harris JR, Markl J Micron 1999 30 6 597-623 (Pubitemid 29492383) (Pubitemid 29492383)
99. Dendritic cells pulsed with a tumor-specifc peptide induce long-lasting Immunity and are effective against murine intracerebral melanoma. Dietrich PY, de Tribolet N Neurosurgery 2002 50 1 164-166 (Pubitemid 43348047) (Pubitemid 43348047)
100. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon JE, Lally-Goss D, McGehee-Norman S, Paolino A, Reardon DA, Friedman AH, Friedman HS et al Mol Cancer Ther 2009 8 10 2773-2779
101. Tumor-specifc peptide vaccination in newly-diagnosed patients with GBM. Heimberger AB, Hussain SF, Aldape K, Sawaya R, Archer GA, Friedman H, Reardon D, Friedman A, Bigner D, Sampson JH J Clin Oncol 2006 24 Suppl 18 Abs 2529
102. Cancer vaccines in combination with multimodality Therapy. Emens LA, Reilly RT, Jaffee EM Cancer TREAT Res 2005 123 227-245
103. Phase II trial of cetuximab in patients with refractory colorectal Cancer that expResses the epidermal growth factor receptor. Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ J Clin Oncol 2004 22 7 1201-1208 (Pubitemid 41079832) (Pubitemid 41079832)
104. A phase II, multicenter study of cetuximab monoTherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining. Wierzbicki R, Jonker DJ, Moore MJ, Berry SR, Loehrer PJ, Youssoufan H, Rowinsky EK Invest New Drugs 2009 October 15 doi:10.1007/s10637-009-9341-6
105. Anti-EGFR monoclonal antibodies in metastatic colorectal Cancer: Time for an individualized approach? Fakih M Expert Rev Anticancer Ther 2008 8 9 1471-1480
106. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Bigner SH, Humphrey PA, Wong AJ, Vogelstein B, Mark J, Friedman HS, Bigner DD Cancer Res 1990 50 24 8017-8022
107. Glioblastoma-derived spheroid cultuRes as an experimental model for analysis of EGFR anomalies. Witusik-Perkowska M, Rieske P, Hułas- Bigoszewska K, Zakrzewska M, Stawski R, Kulczycka-Wojdala D, Bienkowski M, Stoczynska-Fidelus E, GResner SM, Piaskowski S, Jaskolski DJ et al J Neurooncol 2010 Epub ahead of print
108. Tumor heteroGeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Inda MD, Bonavia R, Mukasa A, Narita Y, Sah DWY, Vandenberg S, Brennan C, Johns TG, Bachoo R, Hadwiger P, Tan P et al GeneS DEV 2010 24 16 1731-1745
109. CD133(+) and CD133(-) glioblastoma-derived Cancer stem cells show differential growth characteristics and Molecular profles. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U, Beier CP Cancer Res 2007 67 9 4010-4015 (Pubitemid 46815044) (Pubitemid 46815044)
110. Identifcation of a Cancer stem cell in human brain tumors. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB Cancer Res 2003 63 18 5821-5828 (Pubitemid 37187480) (Pubitemid 37187480)
111. Identifcation of human brain tumour initiating cells. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB Nature 2004 432 7015 396-401 (Pubitemid 39551674) (Pubitemid 39551674)
112. Epidermal growth factor receptor variant III status defnes clinically distinct subtypes of glioblastoma. Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WKA, Colman H, Woo SY et al J Clin Oncol 2007 25 16 2288-2294 (Pubitemid 46954657) (Pubitemid 46954657)
113. An early phase study of an EGFRvIII peptide based vaccine in patients with EGFRvIII expRessing Cancers. Montgomery RB, Disis ML WEB SITE 2002 January 11
114. Dendritic cell vaccine for intracranial tumors I (DC VICTORI). Archer GE, Bigner D, Friedman A, Friedman H, Penne K, Lally-Batts D, Paolino A, Tourt-Uhlig S, Reardon D, Sampson J Neurooncology 2004 6 4 Abs IM-02
115. Immunologic escape after prolonged progRession-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Freidman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA et al J Clin Oncol 2010 28 31 4722-4729
116. Celldex reports third quarter 2010 fnancial Results. Celldex Therapeutics Inc Press Release 2010 November 02
117. ExpRession of nine tumour antigens in a series of human glioblastoma multiforme: InteRest of EGFRvIII, IL-13R2, gp100 and TRP-2 for immunoTherapy. Saikali S, Avril T, Collet B, Hamlat A, Bansard JY, Drenou B, Guegan Y, Quillien V J Neuro ONCOL 2007 81 2 139-148 (Pubitemid 44963972) (Pubitemid 44963972)
118. Inhibition of tumor growth by ribozyme-mediated suppRession of aberrant epidermal growth factor receptor Gene expRession. Yamazaki H, Kijima H, Ohnishi Y, Abe Y, Oshika Y, Tsuchida T, Tokunaga T, Tsugu A, Ueyama Y, Tamaoki N, Nakamura M J Natl Cancer Inst 1998 90 8 581-587 (Pubitemid 28204801) (Pubitemid 28204801)
119. Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA. Halatsch ME, Schmidt U, Bötefür IC, Holland JF, Ohnuma T J Neurosurg 2000 92 2 297-305 (Pubitemid 30071050) (Pubitemid 30071050)
120. SuppRession of EGFRvIII-mediated proliferation and tumoriGenesis of breast Cancer cells by ribozyme. Luo X, Gong X, Tang CK Int J Cancer 2003 104 6 716-721 (Pubitemid 36418508) (Pubitemid 36418508)
121. Synthesis of rindopepimut. American Peptide Company COMpANy COMMUNICATION 2010 September 23
122. EGFRvIII-targeted vaccination Therapy of malignant glioma. Choi BD, Archer GE, Mitchell DA, Heimberger AB, McLendon RE, Bigner DD, Sampson JH Brain Pathol 2009 19 4 713-723